Vertex executives warned that Casgevy, its curative treatment for sickle cell disease, would be slow to reach patients. But ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known ...

Vertex Pharmaceuticals' late-stage pipeline. Vertex Pharmaceuticals' strategy is to develop medicines in areas with high ...

Wondering if Vertex Pharmaceuticals at around US$470 a share is offering fair value, or if you are paying up for quality, you ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

(NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today released its 2025 End‑of‑Year U.S. Sales Tax Rates and Rules Report. Tracking 12,414 U.S. tax ...

China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

Vertex Flooring Presents High-Performance SPC Flooring Designed for Stability, Style, and Durability HOLLISTON, MA, ...